Acromegaly

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Abdominal pain, Acromegaly, Headache, Webcast, Patient, Diarrhea, NDA, FISU World University Games, ID, Endocrinology, Food, Medical school, Pharmaceutical industry

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced positive topline results from PATHFNDR-2, the second of two Phase 3 studies evaluating the efficacy and safety of oral, once-daily investigational paltusotine for the treatment of acromegaly.

Key Points: 
  • “This study demonstrates that paltusotine can provide both symptom control as well as biochemical control in patients who are not currently on pharmacologic treatment.
  • The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine treatment arm and placebo arm.
  • The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants.
  • Following the live event, a replay will be available on the Investors section of the Company’s website.

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Hypoparathyroidism, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million. Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.

Key Points: 
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • We are grateful to the investigators, patients, and patient associations who have supported us to reach these goals,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Retrieved on: 
Tuesday, March 12, 2024
Conference, Acromegaly, Patient, SAN, Carcinoid syndrome, Conference call, Safety, Pharmacokinetics, Therapy, FDA, Pharmaceutical industry

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced positive topline results from its open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and carcinoid syndrome.

Key Points: 
  • “We are very pleased that these results from our Phase 2 study of paltusotine in carcinoid syndrome confirm our decision to move expeditiously toward Phase 3,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
  • “These results highlight the potential of paltusotine to deliver significant benefits to patients living with the debilitating symptoms of carcinoid syndrome.
  • Twenty-six of the 30 participants who completed the randomized treatment phase enrolled in the long-term extension phase of the study.
  • “There is a critical need for better treatment options for patients with neuroendocrine tumors who experience carcinoid syndrome.

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
Professional Services, Health, Other Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Partner, PTHR1, AstraZeneca, Disease, Acromegaly, Patient, Lead, Acquisition, Endocrine disease, Cooley LLP, Investment, Series, Centerview Partners, Alexion, Endocrinology, Hypoparathyroidism

We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.

Key Points: 
  • We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • “Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca.
  • Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Chiesi Global Rare Diseases Launches “Rethink Acromegaly” Campaign to Provide Important Disease Education and Support to the Acromegaly Community

Retrieved on: 
Friday, March 1, 2024
Caregiver, Acromegaly, Health care, Quality of life, Cartilage, Health, Knowledge, Disease, Diagnosis, Growth hormone

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, today announced the launch of Rethink Acromegaly, a disease education program. Intended to provide audiences with the latest information and resources, RethinkAcromegaly.com serves as a resource to empower people living with acromegaly, their caregivers, and healthcare professionals.

Key Points: 
  • Intended to provide audiences with the latest information and resources, RethinkAcromegaly.com serves as a resource to empower people living with acromegaly, their caregivers, and healthcare professionals.
  • Acromegaly is a rare endocrine disorder characterized by excessive growth hormone production, typically stemming from a benign pituitary tumor.
  • "At Chiesi Global Rare Diseases, we understand that developing medicines for underserved patient communities is just one piece of the puzzle.” Giacomo Chiesi, Head of Chiesi Global Rare Diseases, said.
  • “Equipping individuals with rare diseases, caregivers, and their healthcare providers with the knowledge and resources they need to navigate their disease is equally vital.

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Retrieved on: 
Monday, December 18, 2023
Conference, Aes, CS, Acromegaly, Diarrhea, FDA, Headache, Conference call, Carcinoid syndrome, SAN, Abdominal pain, Defecation, Pharmacokinetics, Flushing, ID, Webcast, Patient, Safety, Pharmaceutical industry

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound being developed for the treatment of acromegaly and CS.

Key Points: 
  • “We are very encouraged by these strong initial findings in our Phase 2 study of paltusotine in people with carcinoid syndrome,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics.
  • “These initial results show the potential of paltusotine to significantly reduce both frequency and intensity of bowel movements and flushing, the key carcinoid syndrome symptoms.
  • Thirteen of the 15 participants (87%) who completed the randomized treatment phase enrolled in the long-term extension phase of the study.
  • Crinetics will hold a conference call and live webcast on Monday, December 18 at 5:00 p.m. Eastern Time to discuss the initial findings from the Phase 2 study.

Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Acromegaly, Data, Safety, Carcinoid syndrome, Trial of the century, Somatostatin, Carcinoid, Maintenance, SAN, Pharmaceutical industry

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2023.
  • We are enthusiastic about these upcoming key milestones for the paltusotine franchise.”
    Third Quarter 2023 and Operating Highlights:
    Phase 3 PATHFNDR-1 study met primary and all secondary endpoints.
  • In September 2023, Crinetics announced the pricing of an upsized underwritten public offering of 11,441,648 shares of its common stock at $30.59 per share.
  • Unrestricted cash, cash equivalents, and investments totaled $554.7 million as of September 30, 2023, compared to $334.4 million as of December 31, 2022.

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."

Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment

Retrieved on: 
Wednesday, October 11, 2023
Acromegaly, MBA, NYSE, Acquisition, FOLFIRINOX, Pancreas, PK, Carcinoid syndrome, Safety, Survival, Therapy, Oncolytics Biotech, JV, NEO, ADC, Research, JD, Lung cancer, Patient, Ovarian cancer, CR, PFE, Genelux Corporation, Survival rate, TSX, VC, Public, Medicine, Cancer, FDA, Melanoma, Immunotherapy, Pancreatic Cancer Action Network, FTD, Diagnosis, Glomus tumor, News, Death, ORR, PDAC, IND, ONC, CAD, Growth, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Seagen, Pfizer, Pelareorep

VANCOUVER, British Columbia, Oct. 11, 2023 /PRNewswire/ -- USA News Group - Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A recent study found a nearly 80% global increase in the number of under-50s getting diagnosed with cancer from 1990 to 2019. And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates. However, with strategies such as the "Cancer Moonshot," a $200M boost from a newly formed VC firm, and sustained efforts from the Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer organization, which this year noted the 5-year survival rate is approximately 12%. Many new developments are currently underway from biotech firms searching for new treatments and methods of diagnosis, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Genelux Corporation (NASDAQ: GNLX), Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), Pfizer Inc. (NYSE: PFE) and Seagen Inc. (NASDAQ: SGEN).

Key Points: 
  • And among the most worrying rise is in pancreatic cancer, which comes with extremely low survival rates.
  • "By teaming up with PanCAN, we believe we may be able to expedite development and provide pancreatic cancer patients with a bespoke immunotherapeutic treatment option."
  • Further survival follow up is required to inform our next steps in pancreatic cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen.
  • "We are continuing to advance the ongoing phase 2 trial of SEA-CD40 in melanoma and in non-small cell lung cancer."